BD/Haselmeier
This article was originally published in The Gray Sheet
Executive Summary
BD inks agreement with Germany-based Haselmeier GmbH to form a joint venture for the design, development and exclusive distribution of auto-injecting pen devices, the companies announce Oct. 5. The Swiss-based venture, BD/Medico GmbH, will design hidden-needle injection devices for the self-administration of parenteral drugs. BD is targeting recipients of growth hormones, fertility agents, alpha-interferon for hepatitis, beta-interferon for multiple sclerosis and low molecular weight heparin for deep vein thrombosis. While the devices will be immediately available to pharmaceutical companies, BD estimates a timeframe of 18-24 months before the devices make it to the U.S. market